Dengue drug trial pulled before it even started

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Fever \> 38°C for \< 48 hours and clinical presentation consistent with dengue fever. * Positive NS1 strip assay or reverse-transcriptase polymerase chain reaction (RT-PCR) assay for dengue virus. * Informed consent form signed and dated by the patient. * Subject able to give informed consent and able to comply with all study visits and all study procedures. * Females of childbearing potential should be using and committed to continue using acceptable birth control methods. * Sexual abstinence (inactivity) for 1 month prior to screening through study completion; or * Intrauterine device (IUD) in place for at least 3 months prior to study through study completion; or * Stable hormonal contraception for at least 3 months prior to study through study completion; or * Surgical sterilization (vasectomy) of male partner at least 6 months prior to study. * To be considered of non-childbearing potential, females should be surgically sterilized (bilateral tubal ligation, hysterectomy, or bilateral oophorectomy at least 2 months prior to study) or be post-menopausal and at least 3 years since last menses. Exclusion Criteria * One or more of the following dengue warning signs and symptoms: * Intense and continuous abdominal pain (referred pain or on palpation); * Persistent vomiting; * Fluid accumulation (ascites, pleural effusion, or pericardial effusion); * Postural hypotension and/or collapse; * Painful hepatomegaly \> two centimeters below the right costal margin; * Mucosal bleeding; * Major bleeding (hematemesis and/or melena); * Lethargy and/or irritability; * Diminished urine output; * Hypothermia; * Progressive increase in hematocrit or 20% above baseline or normal for age; * Abrupt drop in platelets; * Respiratory discomfort. * One or more of the following signs and symptoms of severe dengue, such as: * Severe plasma extravasation, leading to shock evidenced by one or more of the following: * Tachycardia; * Cold distal extremities; * Weak, thready pulse; * Slow capillary refill (\> 2 seconds); * Pulse pressure \< 20 mmHg; * Tachypnea; or * Oliguria (\<1.5 mL/kg/hr). * Systolic blood pressure \< 90 mmHg or decrease \>40 mmHg; * Cyanosis; * Fluid accumulation with respiratory discomfort; * Severe bleeding; or * Severe organ impairment, evidenced by one or more of the following: * Liver impairment (AST \>1000 U/L, international normalized ratio \>1.5); * Renal impairment (serum creatinine ≥1.5 mg/dL); or * Myocarditis, pericarditis, or clinical heart failure (by chest x-ray, echocardiography, electrocardiogram, or cardiac enzymes if available). * Female who is pregnant, lactating or of childbearing potential. * Self-reported or suspected congenital or acquired immunodeficiency (including HIV infection); or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the previous 3 months). * Prior vaccination against dengue fever. * Significant chronic illness that, in the opinion of the Investigator, would interfere with study validity, conduct or completion.